Literature DB >> 11848531

Assessment of soft tissue lesions suspicious for liposarcoma by F18-deoxyglucose (FDG) positron emission tomography (PET).

M H Schwarzbach1, A Dimitrakopoulou-Strauss, G Mechtersheimer, U Hinz, F Willeke, S Cardona, N Attigah, L G Strauss, C Herfarth, T Lehnert.   

Abstract

BACKGROUND: F18-deoxyglucose (FDG) positron emission tomography (PET) is a promising imaging technique. The aim of this study was to investigate the use of FDG PET in patients with suspected liposarcomas (LS). PATIENTS AND METHODS: Forty-two masses were studied. The FDG uptake was estimated in tumor (T) and normal tissue (NT). The data were analyzed with respect to pathological findings.
RESULTS: Pathology revealed 11 primary LS, 14 locally recurrent LS, 5 other sarcomas, 1 inflammation, 1 lymphoma and 10 benign lesions. FDG uptake (T-to-NT ratio) in 25 LS corresponded with the histological subtype. Pleomorphic, mixed and myxoid LS showed an increased T-to-NT ratio and were thus visualized. Four out of six well-differentiated LS presented a low FDG uptake. Like subtype, the tumor grade also corresponded to FDG uptake. The T-to-NT ratio of higher grade LS, contrary to low grade LS, was uniformly increased. Primary LS were distinguishable from benign tumors, while other sarcomas, inflammation and lymphoma were not. Recurrence was detected with a sensitivity of 86% and a specificity of 100%. False-negative diagnoses occurred only in well-differentiated recurrences.
CONCLUSION: FDG uptake in LS correlates with the histological subtype and tumor grade. The diagnostic value of FDG PET in LS, therefore, is influenced by histomorphological parameters. Our data suggest that pleomorphic, mixed and higher-grade LS recurrences are preferentially amenable to FDG PET imaging.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11848531

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas.

Authors:  Matthias H M Schwarzbach; Ulf Hinz; Antonia Dimitrakopoulou-Strauss; Frank Willeke; Servando Cardona; Gunhild Mechtersheimer; Thomas Lehnert; Ludwig G Strauss; Christian Herfarth; Markus W Büchler
Journal:  Ann Surg       Date:  2005-02       Impact factor: 12.969

Review 2.  PET/CT in primary musculoskeletal tumours: a step forward.

Authors:  A Lakkaraju; C N Patel; K M Bradley; A F Scarsbrook
Journal:  Eur Radiol       Date:  2010-06-25       Impact factor: 5.315

Review 3.  Musculoskeletal tumours and tumour-like conditions: common and avoidable pitfalls at imaging in patients with known or suspected cancer: Part B: malignant mimics of benign tumours.

Authors:  Gary Ulaner; Sinchun Hwang; Jonathan Landa; Robert A Lefkowitz; David M Panicek
Journal:  Int Orthop       Date:  2013-02-17       Impact factor: 3.075

4.  Staging and Surveillance of Myxoid Liposarcoma: Follow-up Assessment and the Metastatic Pattern of 169 Patients Suggests Inadequacy of Current Practice Standards.

Authors:  Julia D Visgauss; David A Wilson; David L Perrin; Roy Colglazier; Robert French; Jean-Camille Mattei; Anthony M Griffin; Jay S Wunder; Peter C Ferguson
Journal:  Ann Surg Oncol       Date:  2021-05-07       Impact factor: 5.344

5.  ¹⁸F-FDG-PET/CT findings of retroperitoneal tumors: a pictorial essay.

Authors:  Kazuhiro Kitajima; Atsushi Kono; Jyunya Konishi; Yuko Suenaga; Satoru Takahashi; Kazuro Sugimura
Journal:  Jpn J Radiol       Date:  2013-03-01       Impact factor: 2.374

Review 6.  Lipomatous tumours of the head and neck: a spectrum of biological behaviour.

Authors:  Eelco de Bree; Alexander Karatzanis; Jennifer L Hunt; Primož Strojan; Alessandra Rinaldo; Robert P Takes; Alfio Ferlito; Remco de Bree
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-05-07       Impact factor: 2.503

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.